CN1123147A - Iron-supplementing preparation capable of permeating skin and preparation method thereof - Google Patents
Iron-supplementing preparation capable of permeating skin and preparation method thereof Download PDFInfo
- Publication number
- CN1123147A CN1123147A CN 94111555 CN94111555A CN1123147A CN 1123147 A CN1123147 A CN 1123147A CN 94111555 CN94111555 CN 94111555 CN 94111555 A CN94111555 A CN 94111555A CN 1123147 A CN1123147 A CN 1123147A
- Authority
- CN
- China
- Prior art keywords
- iron
- preparation
- supplementing
- permeating skin
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The iron-supplementing preparation for human and animals is prepared by using inorganic or organic ferrous salt which is specially treated and added with skin-permeating promotor to make the preparation with 80-260 mg/ml of iron-content pharmacologic tests and animal tests verified that it has obvious effect of anti-anaemia and promoting-growth with 15.1-22.5% weight-increasing and high survival rate. Advantage: convenient and safe, good effect.
Description
The invention belongs to transdermal iron supplement agent of a kind of prevention, the treatment mankind, domestic animal, particularly piglet iron deficiency anemia and preparation method thereof.
All the time, the domestic and international mankind or domestic animal, traditional iron supplement all adopts injection or oral iron supplement agent, the use of these dosage forms, though can both satisfy the mankind and domestic animal demand to ferrum, but because on the processing technology, the former is complicated, needs bigger investment, cycle is long, technology is loaded down with trivial details, simultaneously in clinical use, especially between poultry, because the injection viscosity is bigger, cause deaeration difficulty and body dyspnea, and injection site irritation and pain and influence piglet and grow, even cause death.Latter Ze Yin piglet iron supplement must be after birth carries out in (preferably harsh 2-8 hours down) in 1-3 days, and this moment piglet except that the sucking of instinct, still fail other foodstuff of free choice feeding, mandatory per os gavages and usually can cause death.
The purpose of this invention is to provide that a kind of technology is simple, cost is low, dosage is few, and the curative effect height is easy to use, and dispenser does not have pain and stimulation, the iron-supplementing preparation capable of permeating skin that security performance is good.
The mechanism of enriching blood of the present invention is such:
The iron ion of transdermal iron supplement of the present invention agent is under the effect of transdermal enhancer, penetrate the animal skin horny layer, pass through microcirculation, directly enter in the blood (ferrous ion in this way, after entering blood, be oxidized to ferric ion at once), and be that transferrins combines with β 1 globulin in the blood plasma, blood plasma ferrum become.Blood plasma ferrum is carrier with the transferrins, be transported to storage such as liver, spleen, bone marrow ferrum tissues after, just form ferritin and store with the apoferritin of these tissues.
The present invention is achieved in that
Inorganic molysite or organic iron salt dissolved in specific solvent, and are heated to 35 °～65 ℃, add dermal osmosis accelerator after the stirring and dissolving again; Also can earlier dermal osmosis accelerator be joined mixing in the specific solvent, add inorganic or organic iron salt again, be heated to 35 °～65 ℃, be stirred to dissolving fully, promptly make the iron-supplementing preparation capable of permeating skin that iron content is 80～260mg/ml.Wherein each component institute consumption is: inorganic or organic iron salt 40～128% (W/V), solvent 30～86% (V/V), transdermal enhancer 2～17% (V/V).
Organic iron salt of indication of the present invention can comprise ferric citrate, ferric ammonium citrate, ferrous succinate, ferric succinate, ferric glycerylphosphate, tartaric acid high ferro ammonium and ferrous lactate.The inorganic molysite of indication comprises ferrous sulfate, ferric perchlorate, ferric chloride, ferrous carbonate, ferrous lactate.The specific solvent of indication can be water, ethanol, ethyl acetate, ethyl oleate, propylene glycol, sulfolane, pyridine and diluted acid.The dermal osmosis accelerator of indication can be dimethyl formamide, dimethyl acetylamide, dimethyl sulfoxine, Laurel nitrogen ketone, lanoline, N-Methyl pyrrolidone, carbamide, carbiphene etc.
The present invention is except that can be made into preparation capable of permeating skin, also can be made into dosage forms such as injection, Emulsion and patch, for the dual curative effect that obtains iron supplement, cures the disease, can also add antibiotic, antimicrobial drug of no incompatibility etc., also can add trace element and hemopoietic essential vitamins such as a little copper, selenium, cobalt, with the raising effect of enriching blood.If layering appears in solution in the preparation process, then can add 0.1%～10% emulsifying agent.If the preparation injection need not to add dermal osmosis accelerator, but will remove the toxic metals of volume in the preparation.
Iron-supplementing preparation capable of permeating skin production technology of the present invention is simple, and cost is low, uses on veterinary clinic, and antagonism anemia and growth promoting effect are all extremely obvious, and increasing weight than blank, 15.1～22.5% dosages are lacked, curative effect is high.Because the present invention is the preparation of a kind of percutaneous dosing, Transdermal absorption, the safest so it is at present all iron supplement agent (oral, injection), to use most convenient, best a kind of of effect.
The embodiment and the application examples of the following stated describe the present invention in detail.
Embodiment 1
In having the 2000ml beaker of glass rod and heating in water bath, add the 150ml propylene glycol, add 15ml Laurel nitrogen ketone, stir, add 557g ferric chloride (FeCl
36H
2O), be warming up to 50 ℃, and constantly stir, till ferric chloride dissolves fully, cool the temperature to room temperature then with glass rod.Other gets the 2.2g sodium selenite and puts in the 100ml small beaker, adds the low amounts of water dissolving.Under the situation that stirs liquor ferri trichloridi, sodium selenite solution is stirred slowly then.Get sample 1.
Embodiment 2
In having the 2000ml beaker of glass rod and heating in water bath, add the 500ml ethyl acetate, add 460g ferric chloride (FeCl again
36H
2O), heat up, temperature is controlled at below 60 ℃, and constantly stirs with glass rod, and is molten entirely until ferric chloride, is cooled to room temperature then, adds the 460ml dimethyl formamide, stirs, and mixing gets sample 2.
Embodiment 3
In having the 2000ml beaker of glass rod and heating in water bath, add 87ml Laurel nitrogen ketone, add 640g ferric chloride (FeCl
36H
2O), heat temperature raising slowly, temperature is controlled at below 50 ℃, and constantly stirs with glass rod, finish until the ferric chloride dissolving, sample 3.
Embodiment 4
In having the 2000ml beaker of glass rod and heating in water bath, add the 200ml ethyl acetate, add 480g ferric chloride (FeCl
36H
2O), heat temperature raising, temperature is controlled at below 60 ℃, and constantly stirs with glass rod, and is molten entirely until ferric chloride, is cooled to room temperature then.Other gets 5g copper chloride, 3g cobaltous chloride, put in the 100ml small beaker, add the low amounts of water dissolving, under the situation that stirs liquor ferri trichloridi, the solution in the small beaker is slowly poured into, place more than 24 hours, and every stirring in 6 hours once, cobalt salt to be added and mantoquita add 15ml Laurel nitrogen ketone after all dissolving again, stir, get sample 4.
Embodiment 5
In having the 2000ml beaker of glass rod and heating in water bath, add 450ml water, add 50ml Laurel nitrogen ketone, add 210g ferrous sulfate (FeSo
47H
2O), add an amount of cosolvent, slowly be warming up to 50 ℃, and constantly stir, molten entirely until ferrous sulfate, get sample 5.
With the content of free iron in the chemical method analytic sample, the results list 1.
| Sample | ????1 | ????2 | ????3 | ????4 | ????5 |
| Free iron mg/ml | ????225 | ????82 | ????262 | ????192 | ????81 |
Application examples 1
1-2 days piglet of birth, every nest is divided into two groups at random, stamps overbit, and one group is
Matched group, one group is test group.Every piglet skin of back of test group is embrocated 1 milliliter in sample, and matched group is not embrocated.Each group all after medication blood sampling in 20 days measure its blood content of hemoglobin (g/dl), and when test and 40 age in days time-divisions another name heavy, piglet dead in the process of the test will not be added up.The results are shown in Table 2 and table 3.
Table 2 piglet is embrocated sample 1 blood hemoglobin table
| Group | Dosage (ml) | The test natural law | The nest number | Each group number | Hemoglobin (g/dl) | Contrast (%) | ||
| Total content | Average content | Increase and decrease | ||||||
| Sample 1 matched group | ????1 ????0 | ?20 ?20 | ?10 ?10 | ?48 ?48 | ?455.04 ?255.84 | ????9.48 ????5.33 | +4.15 ????0 | ??177.86 ?????100 |
Table 2 shows that behind the use sample 1, the piglet blood hemoglobin increases by 77.86% than matched group.
Table 3 piglet is embrocated sample 1 weightening finish situation
| Group | Dosage (ml) | The test natural law | The nest number | Each group number | Body weight (kg) before the medicine | Body weight after 40 days (kg) | Total augment weight (kg) | Average weight gain (kg) | Increase and decrease (kg) | Contrast % |
| Sample 1 matched group | ????1 ????0 | ?40 ?40 | ?10 ?10 | ?47 ?45 | ?68.15 ?66.60 | ?432.78 ?351.45 | ?364.72 ?284.85 | ?7.76 ?6.33 | ?+1.43 ?????0 | ?122.5 ???100 |
Application examples 2
Experimental technique is with application examples 1, and medication changes sample 2 into, and dosage is 2.5ml, and experimental result sees Table 4, table 5
Table 4 piglet is embrocated sample 2 blood content of hemoglobin tables
| Group | Dosage ml | The test natural law | The nest number | Each group number | Hemoglobin (g/dl) | Contrast % | ||
| Total content | Average content | Increase and decrease | ||||||
| Sample 2 matched groups | ?2.5 ???0 | ?20 ?20 | ?10 ?10 | ?52 ?51 | ?490.36 ?273.36 | ?9.43 ?5.36 | ?+4.07 ?0 | ?175.93 ????100 |
Table 5 piglet is embrocated sample 2 weightening finish information slips
| Group | Dosage (ml) | The test natural law | The nest number | Each group number | Body weight (kg) before the medicine | Body weight after 40 days (kg) | Total augment weight (kg) | Average weight gain (kg) | Increase and decrease (kg) | Contrast % |
| Sample 2 matched groups | ?2.5 ???0 | ?40 ?40 | ?10 ?10 | ?50 ?47 | ?73.00 ?68.15 | ?450.00 ?373.65 | ?377.00 ?305.50 | ?7.54 ?6.50 | ?+1.04 ?????0 | ?116.0 ???100 |
Application examples 3
Experimental technique is with application examples 1, and medication changes sample 3 into, and consumption changes 0.8ml into, and experimental result sees Table 6, table 7
Table 6 piglet is embrocated sample 3 blood content of hemoglobin tables
| Group | Dosage ml | The test natural law | The nest number | Each group number | Hemoglobin (g/dl) | Contrast % | ||
| Total content | Average content | Increase and decrease | ||||||
| Sample 3 matched groups | ?0.8 ?0 | ?20 ?20 | ?10 ?10 | ?50 ?49 | ?469.50 ?263.13 | ?9.39 ?5.37 | ?+4.02 ?????0 | ?174.86 ????100 |
Table 7 piglet is embrocated sample 3 weightening finish information slips
| Group | Dosage (ml) | The test natural law | The nest number | Each group number | Body weight (kg) before the medicine | Body weight after 40 days (kg) | Total augment weight (kg) | Average weight gain (kg) | Increase and decrease (kg) | Contrast % |
| Sample 3 matched groups | ?0.8 ???0 | ?40 ?40 | ?10 ?10 | ?49 ?46 | ?73.99 ?68.08 | ?436.10 ?363.40 | ?362.11 ?295.32 | ?7.39 ?6.42 | ?+0.97 ?????0 | ?115.1 ???100 |
By table 2-7 as can be known, the product according to the method for the present invention's proposition is prepared changes dosage exactly, in its effective dose, all can increase the content of test piglet blood hemoglobin and improve rate of body weight gain.
The piglet survival ratio situation
Data according to application examples 1, application examples 2, application examples 3 are added up, arrangement, and the piglet survival ratio situation sees Table 8
Table 8 is embrocated different sample piglet survival ratio tables
| Application examples | Group | A beginning number | 20 top margin of a page numbers | 40 top margin of a page numbers | Survival rate (%) | Increase and decrease % | Contrast % |
| ?1 | Sample 1 matched group | ?49 ?51 | ?48 ?48 | ?47 ?45 | ?95.91 ?88.23 | ?+7.68 ?????0 | ?108.70 ????100 |
| ?2 | Sample 2 matched groups | ?53 ?54 | ?52 ?51 | ?50 ?47 | ?94.33 ?87.03 | ?+7.3 ????0 | ?108.38 ????100 |
| ?3 | Sample 3 matched groups | ?52 ?52 | ?50 ?49 | ?49 ?46 | ?94.23 ?88.46 | ?+5.77 ?????0 | ?106.52 ????100 |
Find out that by table 8 after piglet was embrocated sample 1--3 days, survival rate improved 6.52-8.70%.
Toxicity test:
Selective body focuses on 36 of the healthy mices of 20-25g, gross weight 792.369, counterpoise 22.01g, divide equally three groups at random, test with sample 1, observed 7 days after the medication, first group of every Mus embrocated 0.1ml, and second group of every Mus embrocated 0.2ml, and the 3rd group of every Mus embrocated 0.3ml, observe abnormal phenomena and death condition, and dead mice row cutd open inspection, the result shows that it is safe embrocating the 0.1ml group, that is consumption is perfectly safe in 4.52ml Kg body weight, and we are that 1Kg is with 1ml to user's recommended amounts still more.
Claims (5)
1, a kind of iron-supplementing preparation capable of permeating skin and preparation method thereof comprises inorganic molysite or organic iron salt, solvent and skin penetrant, it is characterized in that: with inorganic molysite or organic iron salt dissolved in specific solvent, and be heated to 35 °-65 ℃, after the stirring and dissolving, add dermal osmosis accelerator again; Also can earlier dermal osmosis accelerator be joined mixing in the specific solvent, add inorganic or organic iron salt again, be heated to 35 °-65 ℃, be stirred to dissolving fully, promptly make the iron-supplementing preparation capable of permeating skin that iron content is 80-260mg/ml; Wherein consumption is: inorganic or organic salt 40～128% (W/V), solvent 30～86% (V/V), transdermal enhancer 2～17% (V/V).
2, iron-supplementing preparation capable of permeating skin as claimed in claim 1 and preparation method thereof is characterized in that said specific solvent, can be water, ethanol, ethyl acetate, ethyl oleate, propylene glycol, sulfolane, pyridine, diluted acid.
3, iron supplement transdermal agent as claimed in claim 1 and preparation method thereof, it is characterized in that said dermal osmosis accelerator can be dimethyl formamide, dimethyl acetylamide, dimethyl sulfoxine, laurocapram, lanoline, N-N-methyl 2-pyrrolidone N-, carbamide, carbiphene etc.
4, iron-supplementing preparation capable of permeating skin as claimed in claim 1 and preparation method thereof is characterized in that adding trace element and vitamin such as a little copper, selenium, cobalt, with the raising effect of enriching blood.
5, iron-supplementing preparation capable of permeating skin as claimed in claim 1 and preparation method thereof is characterized in that adding the antibiotic of no incompatibility, and antimicrobial drug is in order to iron supplement, cure the disease and carry out simultaneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94111555A CN1060647C (en) | 1994-10-21 | 1994-10-21 | Iron-supplementing preparation capable of permeating skin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94111555A CN1060647C (en) | 1994-10-21 | 1994-10-21 | Iron-supplementing preparation capable of permeating skin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1123147A true CN1123147A (en) | 1996-05-29 |
| CN1060647C CN1060647C (en) | 2001-01-17 |
Family
ID=5035411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94111555A Expired - Fee Related CN1060647C (en) | 1994-10-21 | 1994-10-21 | Iron-supplementing preparation capable of permeating skin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1060647C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142751A (en) * | 2012-04-19 | 2013-06-12 | 烟台海研制药有限公司 | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia |
| CN107223784A (en) * | 2017-06-30 | 2017-10-03 | 云南农业大学 | A kind of newborn piglet is adjusted and its application method with iron |
| US11258507B2 (en) | 2015-04-10 | 2022-02-22 | Viasat, Inc. | Ground network for end-to-end beamforming |
| EP3860621A4 (en) * | 2018-10-05 | 2022-07-06 | Ampersand Biopharmaceuticals, Inc. | Iron formulations for topical administration and methods of treatment of iron deficiency |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049788A (en) * | 1989-09-01 | 1991-03-13 | 吴海元 | The preparation method of children's antanemic syrup |
| CN1052050A (en) * | 1989-11-30 | 1991-06-12 | 湖北省农科院畜牧兽医研究所 | Process for preparing injection agent with high fe content |
-
1994
- 1994-10-21 CN CN94111555A patent/CN1060647C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142751A (en) * | 2012-04-19 | 2013-06-12 | 烟台海研制药有限公司 | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia |
| CN103142751B (en) * | 2012-04-19 | 2014-03-26 | 烟台海研制药有限公司 | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia |
| US11258507B2 (en) | 2015-04-10 | 2022-02-22 | Viasat, Inc. | Ground network for end-to-end beamforming |
| US11418254B2 (en) | 2015-04-10 | 2022-08-16 | Viasat, Inc. | Ground network for end-to-end beamforming |
| US11515933B2 (en) | 2015-04-10 | 2022-11-29 | Viasat, Inc. | System and method for return end-to-end beamforming |
| US11843448B2 (en) | 2015-04-10 | 2023-12-12 | Viasat, Inc. | Satellite for end to end beamforming |
| US11973572B2 (en) | 2015-04-10 | 2024-04-30 | Viasat, Inc. | Access node farm for end-to-end beamforming |
| CN107223784A (en) * | 2017-06-30 | 2017-10-03 | 云南农业大学 | A kind of newborn piglet is adjusted and its application method with iron |
| EP3860621A4 (en) * | 2018-10-05 | 2022-07-06 | Ampersand Biopharmaceuticals, Inc. | Iron formulations for topical administration and methods of treatment of iron deficiency |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1060647C (en) | 2001-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gubler | Copper metabolism in man | |
| CN101062042A (en) | Compound vibramycin injection for animals and the preparing method thereof | |
| CN101356954A (en) | Preparation method of anti-stress medicine earthworm small-peptide chelated chromium | |
| CN108403678A (en) | The improvement of chronic kidney disease, prophylactic | |
| CN1141929C (en) | Medicament and method of treating an organism with medicaments | |
| CN1060647C (en) | Iron-supplementing preparation capable of permeating skin and preparation method thereof | |
| DE69728163T2 (en) | COMPOSITION OF AMINO ACIDS | |
| Goodgame et al. | Body weight change and nutritional adequacy in the parenterally alimented rat | |
| Oestreicher et al. | Influence of intraluminal constituents on zinc absorption by isolated, vascularly perfused rat intestine | |
| CN100344291C (en) | Nutritive lead discharging oral liquid and its preparation method | |
| RU2400237C2 (en) | Method of treating osteodystrophia in milk cows in conditions of technogenic province with excess of nickel and lead | |
| EP0496479A1 (en) | NADH and NADPH as energy-substitutes | |
| US5340834A (en) | Method of increasing muscle mass in chickens | |
| Sanchez et al. | Selenium sulfide in tinea versicolor: blood and urine levels | |
| Weiss et al. | Polyethylene glycol induced thirst: A dual stimulatory mechanism? | |
| RU2316323C1 (en) | Method for preventing iron deficiency anemia in piglets | |
| US5543432A (en) | Application of trace elements to animals | |
| RU2010565C1 (en) | Preparation and methods for treating and prophylaxis of acute gastroenteric diseases of new-born calves | |
| RU2623071C1 (en) | Treatment-and-prophylactic chelate iron containing drug for farm animals | |
| RU2785115C1 (en) | Method for activating energy metabolism during the development of pathobiochemical processes in animals | |
| Sudatri et al. | Side effect of long term injection of high dose whitening vitamin C to plasma glucose and cholesterol level | |
| DE1467974A1 (en) | Process for improving the effectiveness of iron preparations and device for carrying out the process | |
| US20030118663A1 (en) | Method and composition for treating diabetes | |
| RU2238730C1 (en) | Medicinal preparation | |
| CN1616104A (en) | Transfusion medicine prepared from xylitol as istonic regulator and various injections separately and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |